These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 22767610

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
    Zhang W, Tan TM, Lim LY.
    Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
    Li J, Liu Y, Zhang J, Yu X, Wang X, Zhao L.
    Drug Des Devel Ther; 2016 Jan; 10():3699-3706. PubMed ID: 27895462
    [Abstract] [Full Text] [Related]

  • 25. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
    Ikemura K, Inoue K, Mizutani H, Oka H, Iwamoto T, Okuda M.
    Eur J Pharmacol; 2012 Sep 05; 690(1-3):192-201. PubMed ID: 22749977
    [Abstract] [Full Text] [Related]

  • 29. Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.
    Kitamura Y, Koto H, Matsuura S, Kawabata T, Tsuchiya H, Kusuhara H, Tsujimoto H, Sugiyama Y.
    Drug Metab Dispos; 2008 May 05; 36(5):807-10. PubMed ID: 18299336
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.
    Rijmers J, Sparidans RW, Acda M, Loos NHC, Epeslidou E, Bui V, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2024 Oct 07; 21(10):5159-5170. PubMed ID: 39312722
    [Abstract] [Full Text] [Related]

  • 32. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
    Matheny CJ, Ali RY, Yang X, Pollack GM.
    Drug Metab Dispos; 2004 Sep 07; 32(9):1008-14. PubMed ID: 15319343
    [Abstract] [Full Text] [Related]

  • 33. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2018 Oct 15; 143(8):2029-2038. PubMed ID: 29744867
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA, Lucas VS.
    Semin Oncol; 1994 Oct 15; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.